Skip to main content
TipRanks
Go Ultimate75% OFF

Zura Bio (ZURA) AI Stock Analysis

598 Followers
ZURA

Zura Bio

(NASDAQ:ZURA)

Select Model
Rating:43Neutral
Price Target:$0.93â–²(0.11% Upside)
Action:reiterated
Date:11/19/26

The score is driven down primarily by weak financial performance (no revenue, widening losses, and heavy cash burn) and bearish technicals (price well below key moving averages with negative MACD). Corporate events add additional risk due to a Phase 2 trial miss and program discontinuation, partially tempered by the company’s debt-free balance sheet and stated cash runway.

Positive Factors
Debt-free balance sheetA debt-free capital structure reduces interest obligations, refinancing exposure, and the risk that creditors constrain clinical investment. Positive equity provides additional financial resilience, although continued losses can still erode that cushion if operating cash use remains elevated.
Negative Factors
Phase 2 trial failureThe failed Phase 2 study is a material pipeline setback because it removes an indication from development and weakens confidence that tibulizumab can deliver consistent benefits across inflammatory diseases. It also leaves remaining programs carrying greater importance for future progress.

Zura Bio (ZURA) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%50%75%100%ZURA-75.20%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$89.63M
Dividend Yield
―
Average Volume (3M)
4.47M
Price to Earnings (P/E)
-0.8
Beta (1Y)
0.86
Revenue Growth
―
EPS Growth
-76.37%
Country
US
Employees
40
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Zura Bio Business Overview & Revenue Model

Company Description

Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα...

Zura Bio Financial Statement Overview

Summary

Financial profile is weak overall: no revenue, widening net losses in TTM, and deeply negative operating/free cash flow indicating significant cash burn. The main offset is a strong leverage position with zero reported debt and positive equity, which reduces near-term solvency risk but does not remove ongoing funding/runway pressure.

Income Statement

18Very Negative

Balance Sheet

62Positive

Cash Flow

27Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit-16.00K00000
EBITDA-94.76M-68.60M-52.39M-60.56M-27.33M8.42M
Net Income-93.53M-68.65M-52.40M-60.36M-25.74M8.42M
Balance Sheet
Total Assets194.63M113.95M179.53M100.84M5.26M140.55M
Cash, Cash Equivalents and Short-Term Investments187.65M109.41M176.50M99.81M1.57M729.22K
Total Debt00007.76M0
Total Liabilities16.97M12.41M19.51M21.29M27.32M10.35M
Stockholders Equity177.66M101.54M146.81M59.33M-32.06M130.20M
Cash Flow
Free Cash Flow-81.69M-64.93M-28.15M-23.05M-13.20M-1.10M
Operating Cash Flow-81.60M-64.81M-28.08M-15.05M-1.20M-1.10M
Investing Cash Flow-90.00K-113.00K-5.08M-8.00M-12.00M-139.38M
Financing Cash Flow130.32M-2.16M109.84M121.29M14.77M141.21M

Zura Bio Technical Analysis

Technical Analysis SentimentNegative
Last Price0.93

Price Trends

50DMA3.54Negative
100DMA4.56Negative
200DMA4.95Negative

Market Momentum

MACD-0.87Positive
RSI24.25Positive
STOCH2.25Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZURA, the sentiment is Negative. The current price of 0.93 is below the 20-day moving average (MA) of 2.57, below the 50-day MA of 3.54, and below the 200-day MA of 4.95, indicating a bearish trend. The MACD of -0.87 indicates Positive momentum. The RSI at 24.25 is Positive, neither overbought nor oversold. The STOCH value of 2.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZURA.

Zura Bio Risk Analysis

Zura Bio disclosed 82 risk factors in its most recent earnings report. Zura Bio reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Zura Bio Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ZURA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PBYIPBYI70Outperform$368.09M14.8017.52%―9.35%-37.15%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
VORVOR45Neutral$1.14B0.06-830.38%―――
ZURAZURA43Neutral$91.74M-0.83-53.97%――-76.37%
CLLSCLLS42Neutral$77.77M-0.79-319.92%―-66.55%-279.52%
PRQRPRQR39Underperform$148.18M-2.47-70.45%―40.51%2.98%

* Healthcare Sector Average

Performance Comparison

0%100%200%ZURAPBYIPRQRCLLSVORDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ZURA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ZURAZura Bio Limited0.93-2.81-75.13%
PBYIPuma Biotechnology7.052.0741.57%
PRQRProQR Therapeutics BV1.04-1.16-52.73%
CLLSCellectis S.A.0.92-4.43-82.80%
VORVor Biopharma, Inc.19.1910.83129.55%

Zura Bio Corporate Events

Business Operations and StrategyProduct-Related Announcements

Zura Bio Discontinues Hidradenitis Suppurativa Development After Trial Miss

Negative
Nov 9, 2026

On November 9, 2026, Zura Bio reported that its Phase 2 TibuSHIELD trial of tibulizumab in adults with moderate-to-severe hidradenitis suppurativa did not meet its primary endpoint or key secondary endpoints. In the 247-participant study, abscess and...

Business Operations and StrategyFinancial Disclosures

Zura Bio Highlights Q3 Results and Tibulizumab Progress

Positive
Oct 27, 2026

On October 27, 2026, Zura Bio reported third quarter 2026 financial results and detailed progress across its tibulizumab clinical programs, underscoring momentum in its pipeline for serious autoimmune and inflammatory diseases. The company said Phase...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 19, 2026